BIAFBioAffinity Technologies Inc
Mkt Cap
$11.16MVolume
103,729.0052W High
$46.5352W Low
$2.34PE Ratio
-0.12BIAF Fundamentals
Price
$2.38Prev Close
$2.48Open
$2.4450D MA
$4.95Beta
1.26Avg. Volume
5.4MEPS (Annual)
-$22.37P/B
-1.10Rev/Employee
$164,246.00bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath Lung, the Companys noninvasive test for lung cancer, today announced...
Business Wire·2d ago
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·14d ago
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·15d ago
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces The...
PR Newswire·21d ago
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the...
Business Wire·21d ago
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces...
PR Newswire·22d ago
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered...
Business Wire·22d ago
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
Zacks·2mo ago
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.
Zacks·4mo ago